Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.58 |
| ▸ | CTSA | P10619 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27776426 | 0.86 | KDM4E (0.50) | MGAMCTSAKDM4EHDAC3HDAC1 | |
| Allylamine SCHEMBL8152484 | 0.86 | MGAM (0.45) | MGAMCTSAKDM4EKMT2AMEN1 | |
| SCHEMBL2881764 | 0.85 | MGAM (0.58) | MGAMKDM4EKMT2AMEN1LMNA | |
| Ethyl Acetate SCHEMBL29178560 | 0.84 | CTSA (0.45) | MGAMCTSAKDM4EKMT2AMEN1 | |
| SCHEMBL10201993 | 0.83 | CTSA (0.45) | MGAMCTSAKDM4EHDAC3HDAC1 | |
| SCHEMBL3282791 | 0.83 | ADORA3 (0.46) | MGAMCTSAKDM4ETDP1TSHR | |
| SCHEMBL4894481 | 0.83 | CTSA (0.42) | MGAMCTSAKDM4ETSHRHDAC3 | |
| SCHEMBL4894482 | 0.81 | CTSA (0.40) | MGAMCTSAKDM4EKMT2AMEN1 | |
| SCHEMBL5210996 | 0.80 | ADRB2 (0.44) | MGAMCTSAHDAC3HDAC1HDAC2 | |
| SCHEMBL12664041 | 0.79 | CTSA (0.43) | MGAMCTSAKDM4ELMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428456-B2 | 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2016-08-30 | — | — | US | claimed |
| EP-2864315-A2 | 1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-HETEROCYCLYL-CARBOXAMIDE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2015-04-29 | — | — | EP | claimed |
| WO-2013190508-A2 | 1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-HETEROCYCLYL-CARBOXAMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-12-27 | — | — | WO | claimed |
| US-20130345199-A1 | 1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-PIPERIDINE-4-CARBOXAMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-26 | — | — | US | claimed |
| EP-2310356-B1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | claimed |
| US-8354441-B2 | Oxazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | claimed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | claimed |
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | GPC BIOTECH AG (DE) | 2008-08-28 | — | — | US | claimed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | claimed |
| US-5652219-A | Hemoregulatory peptides | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-29 | — | — | US | claimed |
| EP-0701446-A4 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORP (US) | 1997-04-23 | — | — | EP | claimed |
| EP-0621788-A4 | HEMOREGULATORY PEPTIDES. | SMITHKLINE BEECHAM CORP (US) | 1997-03-05 | — | — | EP | claimed |
| EP-0725651-A4 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORP (US) | 1997-03-05 | — | — | EP | claimed |
| EP-0725651-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-14 | — | — | EP | claimed |
| EP-0701446-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-03-20 | — | — | EP | claimed |
| WO-1995011693-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-05-04 | — | — | WO | claimed |
| WO-1994027627-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-08 | — | — | WO | claimed |
| EP-0621788-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-02 | — | — | EP | claimed |
| WO-1993013789-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | ROCK2, ROCK1, RHOT2 | MGAM 4115/4885CTSA 3764/4885KDM4E 3145/4885 |
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | MGAM 3693/4885CTSA 2384/4885KDM4E 2352/4885 |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, ADM2, PDE3B | MGAM 3153/4885CTSA 3863/4885KDM4E 2749/4885 |
| US-20130345199-A1 | 1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-PIPERIDINE-4-CARBOXAMIDE DERIVATIVES | CXCR1, CXCR5, CXCR4 | MGAM 4668/4885CTSA 2595/4885KDM4E 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.